Thromboprophylaxis Not Effective After Knee Arthroplasty, Casting

This article originally appeared here.
Share this content:
Thromboprophylaxis Not Effective After Knee Arthroplasty, Casting
Thromboprophylaxis Not Effective After Knee Arthroplasty, Casting

MONDAY, Dec. 5, 2016 (HealthDay News) -- The use of thromboprophylaxis seems not to prevent venous thromboembolism after knee arthroplasty or casting of the lower leg, according to a study published online Dec. 3 in The New England Journal of Medicine.

Raymond A. van Adrichem, M.D., from Leiden University Medical Center in the Netherlands, and colleagues conducted two parallel multicenter randomized trials with blinded outcome evaluation: the POT-KAST trial involving patients undergoing knee arthroscopy and the POT-CAST trial involving patients treated with casting of the lower leg. Patients were randomized to receive a prophylactic dose of low-molecular-weight heparin or no anticoagulant therapy.

The researchers found that venous thromboembolism occurred in 0.7 percent of patients in the treatment group and in 0.4 percent of patients in the control group in the POT-KAST trial (relative risk, 1.6; 95 percent confidence interval, 0.4 to 6.8). Major bleeding occurred in 0.1 percent of patients in each group. Venous thromboembolism occurred in 1.4 percent of the treatment group and 1.8 percent of the control group in the POT-CAST trial (relative risk, 0.8; 95 percent confidence interval, 0.3 to 1.7). There were no major bleeding events.

"Prophylaxis with low-molecular-weight heparin for the eight days after knee arthroscopy or during the full period of immobilization due to casting was not effective for the prevention of symptomatic venous thromboembolism," the authors write.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Single-Payer Health System Bill Moves Forward in California

Single-Payer Health System Bill Moves Forward in California

Not yet clear where money for the single-payer system would come from

Regorafenib Approved for Hepatocellular Carcinoma

Regorafenib Approved for Hepatocellular Carcinoma

It is the first approved treatment for HCC in almost a decade

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Rates of worsening low in patients receiving aflibercept, bevacizumab, or ranibizumab

is free, fast, and customized just for you!

Already a member?

Sign In Now »